Findings

What do systematic reviews say?

9 questions · 10 findings · 2 reviews · Neuromuscular

No studies found 4 · 40%GRADE not reported 2 · 20%Very low 0 · 0%Low 0 · 0%Moderate 2 · 20%High 2 · 20%

Significant improvement in disability within 6 weeks · people with CIDP

Intravenous immunoglobulin leads to higher significant improvement in disability within 6 weeks compared with placebo (high certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 2.4 [1.72, 3.36]
5 studies · 269 participants
High

Change in mean disability score on Rankin scale · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 90 participants
High

Change in mean disability score at 24 weeks or later · people with CIDP

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 117 participants
Moderate

Serious adverse events · people with CIDP

Intravenous immunoglobulin showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy 2024 · Cochrane Headline outcomes only
RR 0.82 [0.36, 1.87]
3 studies · 315 participants
Moderate

Muscle strength · people with inclusion body myositis

2 findings from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 78 participants
GRADE not reported
Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Significant adverse events · people with inclusion body myositis

1 finding from 1 review

Treatment for inclusion body myositis 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 78 participants
GRADE not reported